Goldman says buy this ground-breaking biotech stock poised to rally 75% from here

Now is the time to buy this biotech company as shares could jump more than 75% from here, Goldman Sachs said. Shares of this stock have plummeted more than 64% this year, but Goldman’s price target suggests shares could rally nearly 76% from Tuesday’s close price.

Subscribe to CNBC Pro to see which stock Goldman Sachs thinks could rally after dipping this year.

Subscribe Now

Here are more of today's top stories, exclusive for CNBC Pro subscribers!

CNBC Pro Talks: Fundstrat's Tom Lee says a market rally is coming in the second half. This is how to play it

TUE, AUGUST 02 2022

Finding cheap stocks that are buying back their own shares, based on David Einhorn's methodology

TUE, AUGUST 02 2022

Bank of America says these are the banks to own during uncertain times

TUE, AUGUST 02 2022

Here are Tuesday's biggest analyst calls: Tesla, Apple, Snowflake, Wayfair, Pinterest, Ross & more

TUE, AUGUST 02 2022

Wall Street pros say these small caps are good buys as recession looms — BofA gives one 40% upside

WED, AUGUST 03 2022

These stocks are the key to the market going higher for the rest of the summer

TUE, AUGUST 02 2022

Like getting these emails? Subscribe to CNBC Pro today and get access to unlimited Pro articles, access to Pro live events, stock tips, and money-making investment ideas.

900 Sylvan Avenue, Englewood Cliffs, NJ 07632

Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes and Market Data and Analysis.

Data also provided by THOMSON REUTERS